Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
March 26, 2024 06:30 ET
|
Beam Therapeutics
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
February 28, 2024 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
February 27, 2024 06:30 ET
|
Beam Therapeutics
Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024 Phase 1 Trial Initiation...
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
January 08, 2024 06:30 ET
|
Beam Therapeutics
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
December 14, 2023 06:30 ET
|
Beam Therapeutics
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
November 08, 2023 06:30 ET
|
Beam Therapeutics
Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Lilly Acquires Beam’s Opt-In Rights to Verve Therapeutics’...
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
November 08, 2023 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
October 31, 2023 06:00 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...